Fig. 3From: Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first resultsPlanar scintigraphy (anterior and posterior views) after therapeutic application of [177Lu]Lu-DOTAZOL at a 20 min, b 3 h, c 24 h, and d 168 h in a patient with bone metastases secondary to prostate cancer (patient no. 1)Back to article page